Oncology PracticeBlood and tissue TMB help predict checkpoint inhibition response in NSCLCJune 21, 2018Immuno-oncologyLung Cancer
Oncology PracticeAvelumab does not add punch to ALK inhibitors for ALK+/– NSCLCJune 7, 2018Lung CancerImmuno-oncology
Oncology PracticeNovel antibody shifts ‘eat me/don’t eat me’ balance in refractory NHLJune 6, 2018Immuno-oncologyLymphoma & Plasma Cell DisordersAggressive LymphomasFollicular Lymphoma
Oncology PracticeCheckpoint inhibitor shows promise in advanced squamous-cell carcinomaJune 5, 2018Nonmelanoma Skin CancerImmuno-oncology
Oncology PracticeMRD-negative status signals better outcomes in CAR T–treated ALLJune 5, 2018Immuno-oncologyALLLeukemia, Myelodysplasia, TransplantationImmunotherapyLymphoma & Plasma Cell Disorders
Oncology PracticeMetastatic lung cancer: Pembrolizumab plus chemo prolongs survivalJune 5, 2018Lung CancerImmuno-oncology
Oncology PracticePembrolizumab monotherapy shows activity in advanced recurrent ovarian cancerJune 4, 2018Gynecologic CancerImmuno-oncology
Oncology PracticeCheckpoint inhibitors well tolerated by NSCLC patients with preexisting autoimmune diseaseMay 21, 2018Lung CancerImmuno-oncology
Oncology PracticeCemiplimab impresses in advanced CSCCMay 21, 2018Nonmelanoma Skin CancerImmuno-oncology
Oncology PracticeMultiple solid tumors targeted by concept CAR TMay 17, 2018Sarcoma & GISTPediatricsImmuno-oncologyPediatric Neuroblastoma
Oncology PracticeIs cancer immunotherapy more effective in men than women?May 16, 2018Immuno-oncologyImmunotherapyGenitourinary CancerGastroenterologyRenal Cell CarcinomaMelanomaLung Cancer
Oncology PracticeCheckpoint inhibitors get to patients quicklyMay 10, 2018Renal Cell CarcinomaImmuno-oncologyLung CancerMelanoma
Oncology PracticeNew drugs provide new options in HCCMay 4, 2018Immuno-oncologyGastroenterologyGI OncologyGastrointestinal Cancer
Oncology PracticeEarly results favorable for combo TLR9 agonist + pembro in advanced melanomaApril 23, 2018MelanomaImmuno-oncology
Oncology PracticeKEYNOTE-054: Adjuvant pembrolizumab beat placebo in high-risk resected melanomaApril 16, 2018Immuno-oncologyMelanoma
